| Website | tvm-capital.com |
| Phone | +49 (89) 998 992-0 |
| Employees |
TVM Capital is a global venture and growth capital firm with a 25 year operating track record. From their headquarters in Munich, and their offices in Boston and most recently also New York, they have financed more than 240 emerging companies in technology and the life sciences. During the last 15 years they have become increasingly specialized in these two attractive high-growth sectors. Their key objective as investors is to enhance company growth by harnessing the power to innovate at all levels – technological, strategic, marketing and geographical - incorporating effective international management and securing adequate financial backing.
| Company | Date | Round | Size | Participants |
| Probiodrug | 1/12 | Unattributed | €15M | 6 |
| bluebird bio | 4/11 | Unattributed | $30M | 5 |
| f-star Biotech | 4/11 | Unattributed | €15M | 7 |
| Cambridge Broadband Networks | 12/10 | Unattributed | $16.5M | 5 |
| Anchor Therapeutics | 8/10 | Series B | $10M | 3 |
| Cerenis Therapeutics | 7/10 | Series C | €40M | 7 |
| DIREVO Industrial Biotechnology | 4/10 | Series D | $8.1M | 2 |
| VPIsystems | 3/10 | Unattributed | $4M | 5 |
| bluebird bio | 3/10 | Series B | $35M | 5 |
| DIREVO Industrial Biotechnology | 2/10 | Unattributed | €6M | 2 |
| Probiodrug | 11/09 | Series B | $54M | 8 |
| Ubidyne | 8/09 | Series B | $43M | 4 |
| Rapid Micro Biosystems | 8/09 | Series A | $18.6M | 4 |
| Proteon Therapeutics | 5/09 | Series B | $50M | 8 |
| Cambridge Broadband Networks | 2/09 | Unattributed | $7.5M | 4 |
| Extend Media | 12/08 | Series C | $10M | 3 |
| Silicon Hive | 10/08 | Unattributed | $7M | 3 |
| CommProve | 9/08 | Unattributed | $14M | 3 |
| SpePharm | 8/08 | Unattributed | €26M | 3 |
| BitWave | 8/08 | Series B | $10.2M | 3 |
| Arteris | 5/08 | Series C | $7.5M | 5 |
| Winbox Technologies | 5/08 | Series A | $1.56M | 1 |
| Concert Pharmaceuticals | 4/08 | Series C | $37M | 12 |
| CoreOptics | 4/08 | Unattributed | $25M | 8 |
| Albireo | 2/08 | Series A | $40M | 2 |
| Vivendy Therapeutics | 1/08 | Unattributed | $30.5M | 2 |
| Ascent Therapeutics | 11/07 | Series A | $8M | 3 |
| DIREVO Industrial Biotechnology | 10/07 | Series C | $16.8M | 7 |
| Proteon Therapeutics | 9/07 | Series A | $12M | 4 |
| Arteris | 6/07 | Series B | $8.1M | 4 |
| Netviewer | 5/07 | Unattributed | $12.2M | 2 |
| Silicon Hive | 4/07 | Series A | $10M | 3 |
| Extend Media | 4/07 | Series B | $12M | 3 |
| Hymite | 1/07 | Series B | $11.5M | 4 |
| Concert Pharmaceuticals | 11/06 | Series B | $48.5M | 8 |
| RenaMed Biologics | 9/06 | Unattributed | $40M | 9 |
| Concert Pharmaceuticals | 7/06 | Series A | $10M | 5 |
| CoreOptics | 7/06 | Unattributed | $28M | 6 |
| Cambridge Broadband Networks | 1/06 | Series D | $9M | 3 |
| Impress Software Solutions | 9/05 | Series C | $10M | 5 |
| Ubidyne | 9/05 | Series A | $15.5M | 2 |
| Amnis | 8/05 | Series C | $11.3M | 4 |
| Sirtris Pharmaceuticals | 3/05 | Series B | $27M | 6 |
| VPIsystems | 3/05 | Series C | $9M | 7 |
| Aventeon | 2/05 | Series B | $5M | 3 |
| Sirtris Pharmaceuticals | 12/04 | Series A | $13M | 5 |
| BitWave | 1/04 | Series A | $13M | 3 |
